www.sembiosys.com
SemBioSys Genetics Inc. is a plant biotechnology company with a technology that enables production of high-value pharmaceutical and non-pharmaceutical products in an affordable and sustainable manner.
News
-
11/10/11
SemBioSys shares soar, inks multi-product commercialization deal with China's Tasly -
01/10/10
SemBioSys Genetics appoints Deloitte to initiate potential sale or merger process -
06/01/09
SemBioSys gets US$2.5 mln from option agreement with MannKind for plant-produced insulin
Recent Sector News
-

Dow higher on home sales data, Dell earnings in focus
U.S. equity markets moved higher Tuesday afternoon as investors welcomed a report showing existing home sales surged in April for the first time since January.
-

Dow points to red on Japan downgrade, Apple, Facebook in focus
U.S. equity markets looked set to open lower Tuesday after Fitch Ratings cut Japan’s credit rating, citing rising public debt and slow deficit-reduction efforts.
-

Q1 gold demand underpinned by China, Central Banks and ETFs
Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
-

Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up
Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
-

Facebook boosts public offering by 25%
Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.
-

Snipp plans ambitious growth as mobile marketing takes off
Mobile marketing company Snipp (CVE:SPN) (TSX.V:SPN), which recently listed on the TSX Venture Exchange, is now seeking a listing on the OTC exchange as it continues to grow in a space that is seeing more and more traction from companies looking to boost their marketing efforts.
What do others think of SemBioSys Genetics
Investors interested in SemBioSys Genetics recently viewed
-
Oxford Pharmascience (AIM: OXP) Developing proprietary delivery systems for medicines & supplements -
NeoStem (NYSE AMEX: NBS) . -
Amphion Innovations (LON: AMP) Amphion builds shareholder value in the medical and technology sectors -
ReNeuron (AIM: RENE) Leading stem cell company targeting areas of significant unmet medical need -
Inovio Pharmaceuticals (NYSE AMEX: INO) Leadership in the development of next-generation vaccines


















